Form 4: Tango Therapeutics Director Lesley Ann Calhoun Reports Stock Transactions

Lesley Ann Calhoun, a director at Tango Therapeutics, reported the acquisition and disposal of common stock and stock options.

Summary

• On June 5, 2024, Lesley Ann Calhoun, a director of Tango Therapeutics, engaged in transactions involving the company's stock.
• Calhoun acquired 6,250 shares of common stock through restricted stock units (RSUs) at $0.00, bringing the total owned to 11,250 shares.
• Concurrently, Calhoun sold 5,000 shares at a weighted average price of $7.2078 per share, reducing the direct ownership to 6,250 shares.
• Additionally, Calhoun acquired options to purchase 37,500 shares of common stock at an exercise price of $7.41, which will vest monthly over one year starting July 5, 2024.
• The sale of shares was executed automatically under a pre-arranged Rule 10b5-1 trading plan adopted on November 6, 2023.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions by a company director, without indicating any positive or negative outlook for the company.

Future Outlook

The stock options vest in 12 substantially equal monthly installments over a period of one year beginning on July 5, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

Industry Context

Form 4 filings are standard practice for reporting insider transactions, providing transparency to investors regarding the buying and selling activities of company insiders.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding insider activity.

Key Dates